valbenazine
Neurocrine’s VMAT2 Inhibitor Valbenazine Fails in Phase 3 Trial for Dyskinetic Cerebral Palsy
Neurocrine; valbenazine; VMAT2 inhibitor; dyskinetic cerebral palsy; KINECT-DCP; Phase 3 trial; chorea
Ingrezza, a Neurocrine Biosciences Drug, Receives FDA Approval for Tardive Dyskinesia Treatment
Neurocrine Biosciences, Ingrezza, FDA approval, tardive dyskinesia, neuropsychiatric disorder, valbenazine, first-of-its-kind treatment.